Skip to main content
OpenTrials
Completed

NCT Number: NCT03892902

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

A clinical study to assess next-day driving performance following evening administrations of ACT-541468 in middle-aged and elderly subjects

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Centre for Human Drug Research

Leiden, 2333, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

General criteria:

  • Signed informed consent prior to any study-mandated procedure.
  • Male and female subjects aged between 50 and 80 years (inclusive) at Screening.
  • Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 pre-dose of each treatment period. They must consistently and correctly use a highly effective method of contraception, be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential (i.e., postmenopausal, XY genotype, Turner syndrome, uterine agenesis).

Study-specific criteria

  • Subject has a valid driving license for more than 5 years, has driven at least 3000 km/year on average in the past 2 years.
  • Normal visual acuity (corrected or uncorrected).

Exclusion criteria

General criteria:

  • Pregnant or lactating women.
  • Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results.
  • History or presence of rhythm disorders
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Study-specific criteria:

  • Current or previous diagnosis of insomnia-related disorder according to the Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5) criteria.
  • History of alcoholism, drug abuse, or regular use of sedative drugs or hypnotics within 3 years prior to Screening.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of more than 21 units or an average daily intake of more than 3 units (males), or defined as an average weekly intake of more than 14 units or an average daily intake of more than 2 units (females). One unit is equivalent to a half-pint (approx. 250 mL) of beer or 1 measure (25 mL) of spirits or 1 glass (125 mL) of wine.
  • Modified Swiss Narcolepsy Scale total score < 0 at Screening or history of narcolepsy or cataplexy.
  • Activities that disturb the circadian rhythm (e.g., working night shift, travelling across 3 time zones) within 2 weeks before (each) study treatment.

Treatment and study plan

ACT-541468

Drug

Film-coated tablet for oral use at a dose strength of 50 mg.

Zopiclone 7.5 mg

Drug

Over-encapsulated to maintain blinding.

Placebo

Other

Matching to maintain blinding.

Primary outcomes

  1. Pharmacodynamic endpoint: Driving performance as measured by the SDLB (difference from placebo, cm) using the Green Dino driving simulator - Day 2

    Time frame: On Day 2 at 9 hours post dose. Duration of the test: 1 hour

    SDLP = standard deviation of the lateral position

  2. Pharmacodynamic endpoint: Driving performance as measured by the SDLB (difference from placebo, cm) using the Green Dino driving simulator - Day 5

    Time frame: On Day 5 at 9 hours post dose. Duration of the test: 1 hour

    SDLP = standard deviation of the lateral position

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Registry information

Official study title

A Single-center, Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 4-way Cross-over Study to Assess Next-day Driving Performance Following Single and Multiple Evening Administrations of ACT-541468 in Middle-aged and Elderly Subjects

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 27, 2019
Registry last updated
Oct 31, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.